EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 14 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease August 18, 2021 Will Ponsegromab Be a Game Changer for Cancer Cachexia? October 17, 2024 World Cancer Day 2023: where does the UK stand? February 3, 2023 Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo... June 10, 2025 Load more HOT NEWS Tratamiento agnóstico contra el cáncer: perspectiva de un experto Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... EMA Recommends Granting a Marketing Authorisation for Tislelizumab Research with Integrity – the madness of short methods
